Results 51 to 60 of about 52,456 (284)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

A Prospective Study of the Clinical Profile, Outcome and Evaluation of D-dimer in Cerebral Venous Thrombosis [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Cerebral Venous Thrombosis (CVT) is a well known disease with diverse clinical presentation and causes. With advances in neuroimaging and changing lifestyles, the clinical profile and causes of CVT are changing. D-dimer has been studied
Venkatesh Thammishetti, Subrahmanyam Dharanipragada, Debdatta Basu, Ramesh Ananthakrishnan, Deepanjali Surendiran   +4 more
doaj   +1 more source

Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis

Cytometry Part A, EarlyView.
ABSTRACT Myelofibrosis is a myeloproliferative neoplasm with potential to transform to acute myeloid leukemia. This evolution is unpredictable and current assays lack the sensitivity and applicability needed to predict this transformation. While population‐level data utilizing comprehensive genomic profiling can identify subgroups at higher risk of ...
Ruby M. Hamilton, Ryan J. Collinson, Henry Y. Hui, Zi Yun Ng, Hun S. Chuah, Malcolm Webb, Belinda B. Guo, Wendy N. Erber, Kathy A. Fuller   +8 more
wiley   +1 more source

Effect of therapeutic phlebotomy on plasma volume in polycythemia patients

Global Journal of Transfusion Medicine, 2018
Background: Therapeutic phlebotomy (TP) helps in reducing the red cell mass thereby whole blood viscosity to improve tissue perfusion and oxygen delivery in polycythemia patients.
Mohandoss Murugesan, Soumya Das, Shamee Shastry   +2 more
doaj   +1 more source

Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]

, 2017
We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene, Biagetti, Giacomo, Cosi, Elisabetta, Nichele, Ilaria, Randi, Maria Luigia, Ruggeri, Marco   +5 more
core   +1 more source

ERYTHROPOIESIS REACTION TO TUMOR GROWTH IN LUNG CANCER PATIENTS

Сибирский онкологический журнал, 2017
Background. In addition to the transport of oxygen in tissues, erythrocytes participate in maintaining homeostasis therefore their qualitative and quantitative characterization may reflect a number of changes occurring in the body.
Y. A. Ragulin, O. S. Izmestieva, V. V. Vapnyar, N. V. Severskaya, M. V. Poluektova, S. E. Glebova, I. L. Ershova, V. N. Derbugov, L. P. Zhavoronkov   +8 more
doaj   +1 more source

Is obstructive sleep apnea associated with erythrocytosis? A systematic review and meta‐analysis

Laryngoscope Investigative Otolaryngology, 2022
Objective The aim of this systematic review and meta‐analysis was to investigate the association between obstructive sleep apnea (OSA) and erythrocytosis.
Min‐Seok Rha, Yeonsu Jeong, Jungghi Kim, Chang‐Hoon Kim, Joo‐Heon Yoon, Hyung‐Ju Cho   +5 more
doaj   +1 more source

Preoperative hematocrit levels and postoperative mortality in patients undergoing craniotomy for brain tumors

Frontiers in Oncology, 2023
BackgroundAbnormal hematocrit values, including anemia and polycythemia, are common in patients undergoing craniotomy, but the extent to which preoperative anemia or polycythemia independently increases the risk of mortality is unclear.
Yangchun Xiao, Xin Cheng, Lu Jia, Yixin Tian, Jialing He, Miao He, Lvlin Chen, Pengfei Hao, Tiangui Li, Weelic Chong, Yang Hai, Chao You, Liyuan Peng, Fang Fang, Yu Zhang   +14 more
doaj   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Idiopathic noncirrhotic portal hypertension: current perspectives [PDF]

, 2016
The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe ...
D'AMATI, Giulia, Gioia, Stefania, Nicoletti, Valeria, PENTASSUGLIO, ILARIA, RIGGIO, Oliviero, VALENTE, MICHELE   +5 more
core   +1 more source